Company intelligence / Profile preview

InnovoTEX

Austin, Texas, United Statesinnovotexinc.com ↗

Ownership: Private
Development stage: Preclinical

Overview

INNOVOTEX is developing a proprietary macrocycle-mediated drug delivery platform for targeted cancer therapy. Their approach enables precise delivery of therapeutics to solid tumors, including those that are aggressive or resistant to current treatments. The technology has been clinically de-risked by leveraging a macrocycle core previously used in over 1000 patients. The company has announced breakthrough data presentations at major oncology conferences but does not yet have commercial-stage products[1][3].

Therapeutic areas: Oncology
Modalities: Macrocycle drug conjugates (MDCs)Multi-modal payloads (implied to include small molecules and possibly other therapeutic agents)
Industry: Biotech

Drug pipeline

1 asset

NOVO-111

Preclinical

Beyond the preview

Go deeper on InnovoTEX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InnovoTEX.

Explore the full profile